Literature DB >> 18519666

Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions.

Yali Yang1, Jingxiang Bai, Rulong Shen, Sharron A N Brown, Elena Komissarova, Ying Huang, Ning Jiang, Gregory F Alberts, Max Costa, Luo Lu, Jeffrey A Winkles, Wei Dai.   

Abstract

Polo-like kinase 3 (Plk3) is an important mediator of the cellular responses to genotoxic stresses. In this study, we examined the physiologic function of Plk3 by generating Plk3-deficient mice. Plk3(-/-) mice displayed an increase in weight and developed tumors in various organs at advanced age. Many tumors in Plk3(-/-) mice were large in size, exhibiting enhanced angiogenesis. Plk3(-/-) mouse embryonic fibroblasts were hypersensitive to the induction of hypoxia-inducible factor-1 alpha (HIF-1 alpha) under hypoxic conditions or by nickel and cobalt ion treatments. Ectopic expression of the Plk3-kinase domain (Plk3-KD), but not its Polo-box domain or a Plk3-KD mutant, suppressed the nuclear accumulation of HIF-1 alpha induced by nickel or cobalt ions. Moreover, hypoxia-induced HIF-1 alpha expression was tightly associated with a significant down-regulation of Plk3 expression in HeLa cells. Given the importance of HIF-1 alpha in mediating the activation of the "survival machinery" in cancer cells, these studies strongly suggest that enhanced tumorigenesis in Plk3-null mice is at least partially mediated by a deregulated HIF-1 pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519666      PMCID: PMC3725591          DOI: 10.1158/0008-5472.CAN-07-6182

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.

Authors:  William G Kaelin
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

Review 2.  Hypoxia-inducible factor-1 (HIF-1).

Authors:  Qingdong Ke; Max Costa
Journal:  Mol Pharmacol       Date:  2006-08-03       Impact factor: 4.436

3.  Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha.

Authors:  Ilias Mylonis; Georgia Chachami; Martina Samiotaki; George Panayotou; Efrosini Paraskeva; Alkmini Kalousi; Eleni Georgatsou; Sofia Bonanou; George Simos
Journal:  J Biol Chem       Date:  2006-09-05       Impact factor: 5.157

Review 4.  pVHL's kryptonite: E2-EPF UCP.

Authors:  Michael Ohh
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

5.  Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells.

Authors:  Y Huang; Q Zhao; C-X Zhou; Z-M Gu; D Li; H-Z Xu; T Wiedmer; P J Sims; K-W Zhao; G-Q Chen
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

6.  Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner.

Authors:  Daniela Flügel; Agnes Görlach; Carine Michiels; Thomas Kietzmann
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

7.  p53 stabilization and transactivation by a von Hippel-Lindau protein.

Authors:  Jae-Seok Roe; Hyungsoo Kim; Soon-Min Lee; Sung-Tae Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cell       Date:  2006-05-05       Impact factor: 17.970

Review 8.  Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.

Authors:  E Wolfgang Kuehn; Gerd Walz; Thomas Benzing
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

Review 9.  Targeting polo-like kinase 1 for cancer therapy.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

10.  Identification by targeted differential display of an immediate early gene encoding a putative serine/threonine kinase.

Authors:  P J Donohue; G F Alberts; Y Guo; J A Winkles
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

View more
  54 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

2.  Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.

Authors:  Meghna U Naik; Ngoc T Pham; Kristin Beebe; Wei Dai; Ulhas P Naik
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 3.  Polo-like kinases: structural variations lead to multiple functions.

Authors:  Sihem Zitouni; Catarina Nabais; Swadhin Chandra Jana; Adán Guerrero; Mónica Bettencourt-Dias
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07       Impact factor: 94.444

4.  Polo-like kinase 2 regulates angiogenic sprouting and blood vessel development.

Authors:  Hongbo Yang; Longhou Fang; Rui Zhan; Jeffrey M Hegarty; Jie Ren; Tzung K Hsiai; Joseph G Gleeson; Yury I Miller; JoAnn Trejo; Neil C Chi
Journal:  Dev Biol       Date:  2015-05-22       Impact factor: 3.582

Review 5.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

6.  Mutual regulation between Polo-like kinase 3 and SIAH2 E3 ubiquitin ligase defines a regulatory network that fine-tunes the cellular response to hypoxia and nickel.

Authors:  Cen Li; Soyoung Park; Xiaowen Zhang; Wei Dai; Dazhong Xu
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

Review 7.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

9.  Stimulation of polo-like kinase 3 mRNA decay by tristetraprolin.

Authors:  Thierry J Horner; Wi S Lai; Deborah J Stumpo; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

10.  Hypoxia transiently sequesters mps1 and polo to collagenase-sensitive filaments in Drosophila prometaphase oocytes.

Authors:  William D Gilliland; Dana L Vietti; Nicole M Schweppe; Fengli Guo; Teri J Johnson; R Scott Hawley
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.